# A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

> **NCT02125318** · PHASE2 · COMPLETED · sponsor: **Galena Biopharma, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Thrombocytosis
- Myeloproliferative Neoplasms

## Interventions

- **DRUG:** Anagrelide CR

## Key facts

- **NCT ID:** NCT02125318
- **Lead sponsor:** Galena Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125318, "A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02125318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*